{
    "clinical_study": {
        "@rank": "110874", 
        "arm_group": {
            "arm_group_label": "Study cohort", 
            "description": "Not Applicable"
        }, 
        "biospec_descr": {
            "textblock": "Throat swab"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This carriage study aims to evaluate the presence of meningococcus in Asian populations (and\n      potential for disease) and explore the extent and serogroup distribution of meningococci\n      circulating in the population."
        }, 
        "brief_title": "N. Meningitidis Carriage Study", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Infections, Meningococcal", 
        "condition_browse": {
            "mesh_term": "Meningococcal Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who the investigator believes can and will comply with the requirements of\n             the protocol or subjects who the investigator believes that parent(s)/Legally\n             Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of\n             the protocol.\n\n          -  Written informed consent obtained from the subject/from the parent(s)/LAR of the\n             subject.\n\n          -  Asymptomatic subjects attending a school or university.\n\n          -  A male or female between, and including 5 and 24 years of age at the time of\n             enrollment.\n\n        Exclusion Criteria:\n\n          -  Subjects who have received a meningococcal conjugate vaccine.\n\n          -  Use of any investigational or non-registered product within one week before the\n             enrollment visit.\n\n          -  Acute respiratory tract infection within 14 days of sample collection.\n\n          -  Immune deficiencies, haematological disorders and oncological disease.\n\n          -  Use of steroids or immunosuppressant drugs within 14 days of sample collection.\n\n          -  Administration of antibiotics within the 2 weeks preceding the collection of sample.\n\n          -  Cranio-facial malformations prohibiting the collection of posterior pharyngeal swabs.\n\n          -  Child in care."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "24 Years", 
            "minimum_age": "5 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Healthy subjects aged between 5 and 24 years attending a school or university in the\n        Philippines."
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01808365", 
            "org_study_id": "114991"
        }, 
        "intervention": [
            {
                "arm_group_label": "Study cohort", 
                "description": "Posterior pharyngeal swabs will be tested for the presence of N. meningitidis.", 
                "intervention_name": "Posterior pharyngeal swab", 
                "intervention_type": "Procedure", 
                "other_name": "Throat swab"
            }, 
            {
                "arm_group_label": "Study cohort", 
                "description": "Collection of socio-demographic data and recording of serious adverse events by interview of subjects or subjects' parents/legally acceptable representatives.", 
                "intervention_name": "Data collection", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Neisseria meningitidis", 
            "Philippines", 
            "carriage", 
            "meningococcus"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Manila", 
                    "country": "Philippines"
                }, 
                "name": "GSK Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Philippines"
        }, 
        "number_of_groups": "1", 
        "official_title": "Neisseria Meningitidis Carriage Study", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Philippines: Food and Drug Administration Philippines"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Assessing the carriage prevalence of N.meningitidis using posterior pharyngeal swabs", 
            "safety_issue": "No", 
            "time_frame": "At enrollment (Day 0)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808365"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The serogroup (determined by Polymerase Chain Reaction) of any isolated N. Meningitidis colonies", 
                "safety_issue": "No", 
                "time_frame": "At enrollment (Day 0)"
            }, 
            {
                "measure": "Further characterization of any carried N. meningitidis using Multi Locus Sequence Typing", 
                "safety_issue": "No", 
                "time_frame": "At enrollment (Day 0)"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}